Neurogene (NGNE) Free Cash Flow (2013 - 2026)

Neurogene (NGNE) has 14 years of Free Cash Flow data on file, last reported at -$26.4 million in Q1 2026.

• Quarterly Free Cash Flow fell 22.39% year-over-year to -$26.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$82.1 million (down 15.45% YoY) and the FY2025 annual result came in at -$77.2 million, down 8.3% from the prior year.
• Free Cash Flow retreated to -$26.4 million in Q1 2026, from -$16.5 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of -$9.4 million in Q2 2023 to a low of -$26.4 million in Q1 2026.
• A 5-year average of -$16.6 million and a median of -$16.5 million in 2025 frame the typical range for Free Cash Flow.
• Annual changes were most pronounced in 2023 — Free Cash Flow gained 20.69% — and 2024, when it slumped 72.66%.
• Tracing NGNE's Free Cash Flow over 5 years: stood at -$19.3 million in 2022, then rose by 11.63% to -$17.1 million in 2023, then dropped by 2.45% to -$17.5 million in 2024, then increased by 5.85% to -$16.5 million in 2025, then plunged by 59.94% to -$26.4 million in 2026.
• The last three Free Cash Flow figures came in at -$26.4 million (Q1 2026), -$16.5 million (Q4 2025), and -$19.6 million (Q3 2025), per Business Quant data.